ABBOTT PARK, Ill. — Abbott is set to enroll patients into two late-stage clinical trials designed to evaluate the safety and efficacy of one of its drugs as a treatment for a difficult-to-treat chronic inflammatory skin disease.
Abbott said it will start to enroll patients in two phase-3 trials — M11-313 and M11-810 — which will examine the investigational use of Humira (adalimumab) in adults with moderate to severe hidradenitis suppurativa, a disease characterized by painful, recurrent abscesses and nodules that primarily appear in the groin or under the armpits or breasts. The abscesses and nodules start out as tender, swollen bumps and over time, these lesions can fill with fluid, burst and result in scars, pain and discomfort, Abbott said.
The 36-week, multinational, randomized, double-blind, placebo-controlled studies will include approximately 600 patients with moderate to severe HS and will be conducted at approximately 50 sites worldwide, including sites in Australia, Canada, Europe and the United States.
"Ten years ago, Humira was approved for moderate to severe rheumatoid arthritis and since then has achieved five additional indications to treat millions of patients across a range of immune diseases," said John Medich, divisional VP clinical developmentof immunology at Abbott. "Abbott is committed to investigating adalimumab as a treatment option for patients with hidradenitis suppurativa, and these studies represent another important step in continuing this exploration."